UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

About this update from Urogen Pharma Ltd.

[{"type":"text","content":"\n- Presentation June 11, 2024 at 3:20 PM ET -\n\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference to take place June 10-13, 2024.\n\n\n\n\nGoldman Sachs 45th Annual Healthcare Conference\n\n\n\n\n\n\n\n\nDate/ time:\n\n\n\n\n\n\n\nJune 11, 2024 at 3:20 PM ET\n\n\n\n\n\n\n\n\nFormat:\n\n\n\n\n\n\n\nFireside Chat\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\n\nMiami, FL\n\n\n\n\n\n\n\n\nWebcast Link:\n\n\n\n\n\n\n\nhere\n\n\n\n\n\n\n\nA webcast from the conference will also be available via the Investors section of UroGen’s corporate website, https://investors.urogen.com. A replay will be available for approximately 90 days.\n\n\nAbout UroGen Pharma Ltd.\n\n\nUroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit www.UroGen.com or follow us on X (Twitter), @UroGenPharma.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240605807048/en/\n\nINVESTOR CONTACT:\n\n\nVincent Perrone\nSenior Director, Investor Relations\[email protected]\n609-460-3588 ext. 1093\n\n\nMEDIA CONTACT:\n\n\nCindy Romano\nDirector, Corporate Communications\[email protected]\n609-460-3583 ext. 1083\n\n\nSource: UroGen Pharma Ltd.","length":6350,"tagName":"div"}]

More updates from Urogen Pharma Ltd.